MUSTARGEN (mechlorethamine hydrochloride) by Recordati is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 1949.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
MUSTARGEN (mechlorethamine hydrochloride) is a classic alkylating agent administered by injection, used primarily in hematologic malignancies and cutaneous lymphomas. It works by covalently binding DNA, disrupting cell division and inducing apoptosis. The drug represents a foundational chemotherapy approach with decades of clinical use.
As a legacy product approaching loss of exclusivity with minimal linked job openings, commercial teams are likely lean and focused on maintenance rather than growth initiatives.
Alkylating Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MUSTARGEN represents a career opportunity primarily in mature commercial management and market access roles rather than growth-oriented positions. Professionals joining this product should expect focus on operational efficiency, payer relations, and patient adherence rather than market expansion or innovation leadership.
Worked on MUSTARGEN at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.